CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236
SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by the European Patent Office, all of which significantly expand the Company's intellectual property portfolio.
The USPTO granted U.S. Patent No. 12,291,557, titled, 'CHIMERIC TIM4 RECEPTORS AND USES THEREOF' on May 6, 2025. The granted claims cover certain design aspects of CER-1236, the Company's lead compound. This patent provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains.
Additionally, the European Patent Office has allowed European Patent Application No. 1882166.7 titled, 'CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE' on May 16, 2025. The allowed claims encompass a chimeric engulfment receptor comprising a TIM4 binding domain and TLR2 signaling domain. The allowance of this European patent application expands protection of additional design aspects of CER-1236, which have already been granted in the U.S., Japan, and China.
Finally, the USPTO granted U.S. Patent No. 12,303,551, titled, 'CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,' on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions and methods of use for CER-1236. The patent covers combination of a chimeric engulfment receptor CD4+ T cell (CD4+ CER-T cell) with a chimeric antigen receptor CD8+ T cell (CD8+ CAR-T cell) or T cell receptor CD8+ T cell (CD8+ TCR-T cell), and their use to treat cancer. This type of combination therapy could be an exciting avenue to complement the CER-T cell technology with other powerful anti-cancer therapies. CERo's intellectual property portfolio now includes 9 total patent families with protection out to 2042 in the United States.
With these additional granted patents and allowed application, CER-1236 and its platform technology is supported by 18 total issued patents and allowed patent application internationally.
Chris Ehrlich, CERo Therapeutics CEO, commented, 'We continue to aggressively expand our intellectual property portfolio, as it ensures CERo's success in the market. These patents protect the core innovations of the CER-T technology that differentiate it from other cell therapies and demonstrate the true novelty of our design . We continue to seek a robust range of patents across multiple geographies that cover this technology in general, and CER-1236 in particular. The appreciation of the novelty of the CER-T technology by the patent offices validates the innovation and therapeutic potential of this approach, and we believe that we will continue to grow the portfolio. In the near term, we anticipate updates on our clinical trial progress in AML, and the announcement of initiating human trials to treat ovarian and non-small cell lung cancers.'
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:Chris EhrlichChief Executive Officerchris@cero.bio
Investors:CORE IRinvestors@cero.bio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Why American Airlines Stock Tumbled Today
Key Points American Airlines beat on sales and earnings this morning. Revenues held steady year over year, but profits declined 10%. American Airlines says it will lose money in Q3, and could lose money for the full year as well. 10 stocks we like better than American Airlines Group › American Airlines (NASDAQ: AAL) stock sank 7.2% through 10:55 a.m. ET Thursday despite reporting an earnings beat for Q2 this morning. Analysts forecast the airline company would earn $0.77, adjusted for one-time items, on $14.3 billion in Q2 sales. In fact, the airline earned $0.95 on sales of $14.4 billion. American Airlines Q2 earnings What's bad about that? Combing through the numbers, here's what we find: Earnings as calculated according to generally accepted accounting principles (GAAP) were lower than the adjusted figure of $0.91. This was down 10% from what AA earned a year ago, despite quarterly revenue remaining roughly flat. So obviously, profit margins declined. But why? Well, fuel costs were lower in Q2 2025 than a year ago, but salaries, wages, and benefits cost 11% more, and landing fees grew 7%. Those were among the biggest changes that stand out. Is American Airlines stock a sell? I doubt these costs are what's upset investors today, however. Looming larger are concerns about "macro weaknesses" in the economy that are affecting company guidance. Although American Airlines management says it doesn't necessarily see a reason to worry right now, it worries anyway -- and after reporting its big Q2 profit, told investors it might lose as much as $0.60 per share in Q3, while full-year results could be as good as a $0.80 per-share profit... or as bad as a $0.20 per-share loss. That's a pretty wide range of potential outcomes for the year, and the only thing AA seems certain of is that it will definitely lose money in the current quarter. With a market cap of only $7.8 billion but more than $28 billion in debt and losses on the horizon, maybe investors should worry about AAL stock, too. Should you buy stock in American Airlines Group right now? Before you buy stock in American Airlines Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and American Airlines Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $634,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,799!* Now, it's worth noting Stock Advisor's total average return is 1,037% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why American Airlines Stock Tumbled Today was originally published by The Motley Fool Sign in to access your portfolio
The Hill
6 minutes ago
- The Hill
Is Giorgia Meloni the ‘Iron Lady' for the Trump era?
In the twilight of the Cold War, the West's resurgence was defined by the extraordinary partnership between President Ronald Reagan, Prime Minister Margaret Thatcher and Pope John Paul II. Their alliance — grounded in a shared vision of political freedom, faith and economic liberty — reshaped the world. Today, as President Trump works to remake America's place in the world and Pope Leo launches his papacy with strong calls for human dignity in the AI era, one wonders who in Europe can rise to the moment as Thatcher once did. The answer, increasingly, seems to be Italian Prime Minister Giorgia Meloni. The 2020s are witnessing the rise of a new transatlantic alliance in which Meloni is poised to play the pivotal European role. As the continent's political center struggles with fragmentation and fatigue, Meloni has emerged not just as a survivor, but as the most powerful person in Europe, a bridge between Washington and Brussels and the architect of a new conservative order. Why does Meloni matter now? Recall what made the Thatcher-Reagan partnership so exceptional. Thatcher was not Reagan's sidekick but his intellectual peer and sometimes his challenger. Both leaders were outsiders who stormed the establishment, preaching the virtues of free enterprise and national renewal. Their rapport was legendary, rooted in mutual respect, frequent communication and a willingness to push each other toward bolder action. Thatcher's influence was felt not only in her steadfast support for Reagan's confrontation with the Soviet Union but also in her ability to shape his thinking. Their partnership was not frictionless; disagreements over the Falklands, Grenada and economic policy occasionally flared, but their unity was a force multiplier for the Western world. Fast forward to 2025, and Europe is searching for a new Thatcher — a leader with the vision, resolve and political skill to partner with an assertive America. Enter Meloni, Italy's first female prime minister. Meloni's rise is Thatcherite in its improbability. Once dismissed as a neo-fascist firebrand, she has transformed her Brothers of Italy party from the fringes to the mainstream, presiding over a stable government in a country known for its political chaos. Her coalition dominates Italian politics, and her approval ratings have remained robust even as she pursues controversial reforms. What sets Meloni apart, however, is her growing stature on the world stage. She has become the European leader most closely aligned with Trump, earning his praise and trust. She was the only EU head of government invited to Trump's 2025 inauguration — a symbolic nod to her emerging role as the continent's conservative standard-bearer. The parallels with the Reagan-Thatcher era are striking. Like Thatcher, Meloni is a conviction politician with a talent for coalition-building and a knack for bending events to her will. She has used her position to shift the European debate on migration, security and sovereignty — championing policies that have been adopted, in some form, by Brussels and emulated by other European leaders. Meloni's diplomatic skills have also been on display in her dealings with Washington and Brussels. She has managed to maintain Italy's support for Ukraine and NATO while also cultivating ties with Trump's inner circle and other right-wing populists. Her ability to bridge the gap between an increasingly nationalist America and a fragmented Europe is reminiscent of Thatcher's role as the indispensable transatlantic interlocutor. Of course, the analogy is not perfect. Meloni's Italy is not the U.K. of the 1980s, and today's geopolitical landscape is more multipolar. Thatcher's Britain was a nuclear power and America's closest ally. Meloni's Italy, while influential, does not command the same global clout. Europe today is more fractured, and the threats it faces — migration, energy insecurity, technological disruption — are different from the existential menace of Soviet communism. Yet Meloni's impact is undeniable. She has demonstrated that European leaders can still shape the global agenda, provided they combine ideological clarity with political pragmatism. Like Thatcher, Meloni is willing to challenge orthodoxy and take risks, even at the cost of controversy. As Trump seeks to recast America's role in the world, he needs a European partner who is more than a cheerleader — someone who can match him in vision and tenacity. Meloni, with her blend of conviction, charisma and strategic sense, is uniquely positioned to play that part. The Reagan-Thatcher-John Paul II alliance changed the course of history. Whether Meloni and Trump can forge a partnership of similar consequence remains to be seen. But as Europe's new power broker, Meloni has already shown she is ready to step onto the world stage — and perhaps, like Thatcher before her, help shape the destiny of the West.
Los Angeles Times
6 minutes ago
- Los Angeles Times
The U.S. fertility rate reached a new low in 2024, CDC data show
NEW YORK — The fertility rate in the U.S. dropped to an all-time low in 2024 with less than 1.6 kids per woman, new federal data released Thursday show. The U.S. was once among only a few developed countries with a rate that ensured each generation had enough children to replace itself — about 2.1 kids per woman. But it has been sliding in America for close to two decades as more women are waiting longer to have children or never taking that step at all. The new statistic is on par with fertility rates in western European countries, according to World Bank data. Alarmed by recent drops, the Trump administration has taken steps to increase falling birth rates, such as issuing an executive order meant to expand access to and reduce costs of in vitro fertilization and backing the idea of 'baby bonuses' that might encourage more couples to have kids. But there's no reason to be alarmed, according to Leslie Root, a University of Colorado Boulder researcher focused on fertility and population policy. 'We're seeing this as part of an ongoing process of fertility delay. We know that the U.S. population is still growing, and we still have a natural increase — more births than deaths,' she said. The U.S. Centers for Disease Control and Prevention released the statistic for the total fertility rate with updated birth data for 2024. In the early 1960s, the U.S. total fertility rate was around 3.5, but plummeted to 1.7 by 1976 after the Baby Boom ended. It gradually rose to 2.1 in 2007 before falling again, aside from a 2014 uptick. The rate in 2023 was 1.621, and inched down in 2024 to 1.599, according to the CDC's National Center for Health Statistics. Birth rates are generally declining for women in most age groups — and that doesn't seem likely to change in the near future, said Karen Guzzo, director of the Carolina Population Center at the University of North Carolina. People are marrying later and also worried about their ability to have the money, health insurance and other resources needed to raise children in a stable environment. 'Worry is not a good moment to have kids,' and that's why birth rates in most age groups are not improving, she said. Asked about birth-promoting measures outlined by the Trump administration, Guzzo said they don't tackle larger needs like parental leave and affordable child care. 'The things that they are doing are really symbolic and not likely to budge things for real Americans,' she said. The CDC's new report, which is based on a more complete review of birth certificates than provisional data released earlier this year, also showed a 1% increase in births — about 33,000 more — last year compared to the prior year. That brought the yearly national total to just over 3.6 million babies born. But this is different: The provisional data indicated birth rate increases last year for women in their late 20s and 30s. However, the new report found birth rate declines for women in their 20s and early 30s, and no change for women in their late 30s. What happened? CDC officials said it was due to recalculations stemming from a change in the U.S. Census population estimates used to compute the birth rate. That's plausible, Root said. As the total population of women of childbearing age grew due to immigration, it offset small increases in births to women in those age groups, she said. Stobbe writes for the Associated Press. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
